Sarepta Therapeutics (NASDAQ:SRPT) is scheduled to issue its quarterly earnings data after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.
Sarepta Therapeutics (NASDAQ SRPT) opened at $63.91 on Friday. The company has a market capitalization of $4,130.00, a P/E ratio of -31.33 and a beta of 1.49. Sarepta Therapeutics has a 52-week low of $28.14 and a 52-week high of $68.90. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.
A number of analysts recently issued reports on the company. HC Wainwright set a $75.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Monday, February 12th. Oppenheimer restated a “buy” rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. BidaskClub downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 10th. Royal Bank of Canada assumed coverage on Sarepta Therapeutics in a research report on Monday, January 22nd. They issued an “outperform” rating for the company. Finally, Leerink Swann restated an “outperform” rating and issued a $77.00 price target on shares of Sarepta Therapeutics in a research report on Friday, January 19th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have issued a buy rating to the stock. Sarepta Therapeutics has an average rating of “Buy” and an average target price of $66.15.
In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now directly owns 13,333 shares in the company, valued at $745,181.37. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 9.60% of the stock is currently owned by company insiders.
WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/24/sarepta-therapeutics-srpt-set-to-announce-quarterly-earnings-on-monday.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.